Bristol-Myers Squibb And Gritstone Oncology Enter Clinical Research Collaboration
Bristol-Myers Squibb Company and Gritstone Oncology today announced that the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Gritstone’s personalized neoantigen immunotherapy, Granite-001, which comprises sequential delivery of neoantigens to patients within an adenovirus-based vector (prime) and a self-replicating RNA-based vector (boost), in combination with Bristol-Myers Squibb’s programmed death-1 (PD-1) immune…
FDA Places Partial Clinical Hold on Three Opdivo Clinical Trials
Bristol-Myers Squibb provides an update on three Opdivo-based combination clinical studies in multiple myeloma. The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on CA209602 (CheckMate-602), CA209039 (CheckMate-039) and CA204142, three clinical trials investigating Opdivo (nivolumab)-based combinations in patients with relapsed or refractory multiple myeloma. This partial clinical hold is related to risks…
Bristol-Myers Squibb Names Dr. Thomas J. Lynch, Jr. to Key Post
Bristol-Myers Squibb appoints Dr. Thomas J. Lynch, Jr., executive vice president and chief scientific officer. Bristol-Myers Squibb Company announced that it has appointed Dr. Thomas J. Lynch, Jr., 56, executive vice president and chief scientific officer, effective March 16, 2017. He succeeds Dr. Francis Cuss, 62, who will retire from the company. Dr. Cuss will serve…
Bristol-Myers Squibb Appoints Three New Independent Directors
Bristol-Myers Squibb Company announced that it has appointed Robert J. Bertolini, Matthew W. Emmens and Theodore R. Samuels to its board of directors, effective immediately. In connection with these appointments, the board will temporarily expand to 14 directors until the 2017 Annual Meeting, to be held on May 2, 2017. Only 11 directors will stand for election at the meeting. The…
